Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries

被引:216
作者
Bont L. [1 ]
Checchia P.A. [2 ]
Fauroux B. [3 ]
Figueras-Aloy J. [4 ]
Manzoni P. [5 ]
Paes B. [6 ]
Simões E.A.F. [7 ]
Carbonell-Estrany X. [8 ]
机构
[1] University Medical Center Utrecht, Utrecht
[2] Baylor College of Medicine, Texas Children’s Hospital Houston, Texas
[3] Necker University Hospital and Paris 5 University, Paris
[4] Hospital Clínic, Catedràtic de Pediatria, Universitat de Barcelona, Barcelona
[5] Neonatology and NICU, Sant’Anna Hospital, Turin
[6] Department of Pediatrics (Neonatal Division), McMaster University, Hamilton, ON
[7] Colorado School of Public Health, University of Colorado School of Medicine, Aurora, CO
[8] Hospital Clinic, Institut d’Investigacions Biomediques August Pi Suñer (IDIBAPS), Barcelona
关键词
Acute respiratory infection; Bronchiolitis; Burden; Epidemiology; Lower respiratory tract infection; Respiratory syncytial virus;
D O I
10.1007/s40121-016-0123-0
中图分类号
学科分类号
摘要
Introduction: The REGAL (RSV [respiratory syncytial virus] Evidence—a Geographical Archive of the Literature) series provides a comprehensive review of the published evidence in the field of RSV in Western countries over the last 20 years. This first of seven publications covers the epidemiology and burden of RSV infection. Methods: A systematic review was undertaken for articles published between Jan 1, 1995 and Dec 31, 2015 across PubMed, Embase, The Cochrane Library, and Clinicaltrials.gov. Studies reporting data for hospital visits/admissions for RSV infection among children (≤18 years of age), as well as studies reporting RSV-associated morbidity, mortality, and risk factors were included. Study quality and strength of evidence (SOE) were graded using recognized criteria. Result: 2315 studies were identified of which 98 were included. RSV was associated with 12–63% of all acute respiratory infections (ARIs) and 19–81% of all viral ARIs causing hospitalizations in children (high SOE). Annual RSV hospitalization (RSVH) rates increased with decreasing age and varied by a factor of 2–3 across seasons (high SOE). Studies were conflicting on whether the incidence of RSVH has increased, decreased, or remained stable over the last 20 years (moderate SOE). Length of hospital stay ranged from 2 to 11 days, with 2–12% of cases requiring intensive care unit admission (moderate SOE). Case-fatality rates were <0.5% (moderate SOE). Risk factors associated with RSVH included: male sex; age <6 months; birth during the first half of the RSV season; crowding/siblings; and day-care exposure (high SOE). Conclusion: RSV infection remains a major burden on Western healthcare systems and has been associated with significant morbidity. Further studies focusing on the epidemiology of RSV infection (particularly in the outpatient setting), the impact of co-infection, better estimates of case-fatality rates and associated risk factors (all currently moderate/low SOE) are needed to determine the true burden of disease. Funding: Abbvie. © 2016, The Author(s).
引用
收藏
页码:271 / 298
页数:27
相关论文
共 113 条
[1]  
Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., Et al., Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis, Lancet, 375, pp. 1545-1555, (2010)
[2]  
Haerskjold A., Kristensen K., Kamper-Jorgensen M., Andersen A.M.N., Ravn H., Stensballe L.G., Risk factors for hospitalization for respiratory syncytial virus infection: a population-based cohort study of Danish children, Pediatr Infect Dis J., 35, pp. 61-65, (2016)
[3]  
Glezen W.P., Taber L.H., Frank A.L., Kasel J.A., Risk of primary infection and reinfection with respiratory syncytial virus, Am J Dis Child, 140, pp. 543-546, (1986)
[4]  
Gil-Prieto R., Gonzalez-Escalada A., Marin-Garcia P., Gallardo-Pino C., Gil-de-Miguel A., Respiratory syncytial virus bronchiolitis in children up to 5 years of age in Spain: epidemiology and comorbidities: an observational study, Medicine (Baltimore), 94, (2015)
[5]  
Simoes E.A., DeVincenzo J.P., Boeckh M., Bont L., Crowe J.E., Griffiths P., Et al., Challenges and opportunities in developing respiratory syncytial virus therapeutics, J Infect Dis, 211, pp. S1-S20, (2015)
[6]  
Vicente D., Montes M., Cilla G., Perez-Yarza E.G., Perez-Trallero E., Hospitalization for respiratory syncytial virus in the paediatric population in Spain, Epidemiol Infect, 131, pp. 867-872, (2003)
[7]  
Fjaerli H.O., Farstad T., Bratlid D., Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993–2000: a population-based retrospective study, BMC Pediatr., 4, (2004)
[8]  
Greenough A., Alexander J., Burgess S., Bytham J., Chetcuti P.A.J., Hagan J., Et al., Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection, Arch Dis Child, 89, pp. 673-678, (2004)
[9]  
Paramore L.C., Ciuryla V., Ciesla G., Liu L., Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases, Pharmacoeconomics., 22, pp. 275-284, (2004)
[10]  
Horn S.D., Smout R.J., Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes, J Pediatrics., 143, pp. S133-S141, (2003)